192 related articles for article (PubMed ID: 22388646)
21. When to initiate and discontinue biologic treatments for rheumatoid arthritis?
Chatzidionysiou K; van Vollenhoven RF
J Intern Med; 2011 Jun; 269(6):614-25. PubMed ID: 21261760
[TBL] [Abstract][Full Text] [Related]
22. TNF inhibitors - new and old agents for rheumatoid arthritis.
Simsek I
Bull NYU Hosp Jt Dis; 2010; 68(3):204-10. PubMed ID: 20969553
[TBL] [Abstract][Full Text] [Related]
23. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors.
Kapetanovic MC; Roseman C; Jönsson G; Truedsson L; Saxne T; Geborek P
Arthritis Rheum; 2011 Dec; 63(12):3723-32. PubMed ID: 21834061
[TBL] [Abstract][Full Text] [Related]
24. Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis.
Wolfe F; Rasker JJ; Boers M; Wells GA; Michaud K
Arthritis Rheum; 2007 Aug; 57(6):935-42. PubMed ID: 17665487
[TBL] [Abstract][Full Text] [Related]
25. Anti-TNF therapy: safety aspects of taking the risk.
Rosenblum H; Amital H
Autoimmun Rev; 2011 Jul; 10(9):563-8. PubMed ID: 21570495
[TBL] [Abstract][Full Text] [Related]
26. [Can the medication in patients with rheumatoidarthritis in remission be stopped?].
Nóvoa Medina FJ; Francisco Hernández F
Reumatol Clin; 2012; 8(1):39-41. PubMed ID: 22178253
[TBL] [Abstract][Full Text] [Related]
27. Anti-TNF in rheumatoid arthritis: an overview.
Radner H; Aletaha D
Wien Med Wochenschr; 2015 Jan; 165(1-2):3-9. PubMed ID: 25651945
[TBL] [Abstract][Full Text] [Related]
28. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
Komano Y; Tanaka M; Nanki T; Koike R; Sakai R; Kameda H; Nakajima A; Saito K; Takeno M; Atsumi T; Tohma S; Ito S; Tamura N; Fujii T; Sawada T; Ida H; Hashiramoto A; Koike T; Ishigatsubo Y; Eguchi K; Tanaka Y; Takeuchi T; Miyasaka N; Harigai M;
J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482
[TBL] [Abstract][Full Text] [Related]
29. [Biologics: current therapeutic strategies for rheumatoid arthritis].
Tanaka Y
Nihon Rinsho; 2007 Jul; 65(7):1179-84. PubMed ID: 17642229
[TBL] [Abstract][Full Text] [Related]
30. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis.
Wu E; Chen L; Birnbaum H; Yang E; Cifaldi M
Curr Med Res Opin; 2008 Aug; 24(8):2229-40. PubMed ID: 18577308
[TBL] [Abstract][Full Text] [Related]
31. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis.
Haraoui B
J Rheumatol Suppl; 2005 Jan; 72():46-7. PubMed ID: 15660467
[TBL] [Abstract][Full Text] [Related]
32. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs.
Cantini F; Niccoli L; Nannini C; Cassarà E; Pasquetti P; Olivieri I; Salvarani C
Rheumatology (Oxford); 2008 Jun; 47(6):872-6. PubMed ID: 18400836
[TBL] [Abstract][Full Text] [Related]
33. [Infliximab in the treatment of rheumatoid arthritis].
Akahoshi T; Watabe H
Nihon Rinsho; 2002 Dec; 60(12):2378-83. PubMed ID: 12510365
[TBL] [Abstract][Full Text] [Related]
34. Optimizing treatment with biologics.
Mader R; Keystone E
J Rheumatol Suppl; 2007 Nov; 80():16-24. PubMed ID: 17985419
[TBL] [Abstract][Full Text] [Related]
35. Anti-TNFα discontinuation in rheumatoid and psoriatic arthritis: is it possible after disease remission?
Chimenti MS; Graceffa D; Perricone R
Autoimmun Rev; 2011 Aug; 10(10):636-40. PubMed ID: 21536151
[TBL] [Abstract][Full Text] [Related]
36. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study.
van den Broek M; Klarenbeek NB; Dirven L; van Schaardenburg D; Hulsmans HM; Kerstens PJ; Huizinga TW; Dijkmans BA; Allaart CF
Ann Rheum Dis; 2011 Aug; 70(8):1389-94. PubMed ID: 21515916
[TBL] [Abstract][Full Text] [Related]
37. [Indications for and use of biologics in early rheumatoid arthritis based on the evidence].
Takeuchi T
Nihon Rinsho; 2009 May; 67(5):1043-9. PubMed ID: 19432131
[TBL] [Abstract][Full Text] [Related]
38. Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry.
Kavanaugh A; Lee SJ; Curtis JR; Greenberg JD; Kremer JM; Soto L; Etzel CJ; Cox V; Yoshida K; Reed GW; Solomon DH
Ann Rheum Dis; 2015 Jun; 74(6):1150-5. PubMed ID: 25471471
[TBL] [Abstract][Full Text] [Related]
39. Discontinuation of biologics in patients with rheumatoid arthritis.
Tanaka Y; Hirata S; Saleem B; Emery P
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S22-7. PubMed ID: 24129132
[TBL] [Abstract][Full Text] [Related]
40. Optimizing the expediency of TNFi in rheumatoid arthritis: offering a TNFi holiday in patients having reached low-disease activity in the maintenance phase.
van Ingen IL; Lamers-Karnebeek F; Jansen TL
Expert Opin Biol Ther; 2014 Dec; 14(12):1761-7. PubMed ID: 25366268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
